Filing Flows › Heron Therapeutics (HRTX) › Guidance & outlook

Heron Therapeutics (HRTX) guidance and outlook

Heron Therapeutics (HRTX) gave its guidance on Nov 9, 2026: Free cash flow $45.0M–$60.0M for FY2026; Free cash flow $45.0M–$60.0M for FY2027. Heron Therapeutics' 10-Q filed Nov 9, 2026 makes 11 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 9, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 9, 2026

• This section provides a general description of our business and operating expenses, as well as other matters that we believe are important to understanding our results of operations and financial condition and in anticipating future trends.
• This section contains a discussion of the accounting estimates that require a significant level of estimation uncertainty, and changes in which are reasonably likely to have a material effect on our financial condition or results of operations.
• Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
• ZYNRELEF will continue to qualify under the Non-Opioid Policy for Pain Relief with the J-code and will be reimbursed outside the surgical supply package for Medicare, aligning with the policy goals to remove financial barriers to qualifying non-opioid pain management options.
• aggregate shares of CorMedix common stock issued under the Asset Purchase Agreement to exceed 19.9% of the CorMedix common stock outstanding as of the closing of the Asset Sale will be paid in cash), if and when payable, on the terms set forth in the Asset Purchase Agreement and (v) assume certain of the Company's liabilities as specified in the Asset Purchase Agreement.
• The Asset Sale, which has been unanimously approved by the board of directors of the Company (the "Board"), is currently expected to close in the first quarter of 2027, subject to approval by the Company's stockholders and the satisfaction of other customary closing conditions.
• If the Asset Sale closes, the Company will exit the operation of its current biotechnology business and other historical operations, but it does not intend to liquidate and will remain a publicly traded company.
• It is currently uncertain what businesses or assets the Company may acquire or invest in following the closing of the Asset Sale, and the Board intends to evaluate opportunities to create value for the benefit of stockholders.
• If the payment of the debt is accelerated, absent any additional funding, cash flows from our operations will be insufficient to repay such debt in full.
• Therefore, if all outstanding amounts under the Working Capital Facility Agreement are accelerated, management expects there will be substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
• The completion of the Asset Sale is subject to approval by the Company’s stockholders and the satisfaction of other customary closing conditions, and there can be no assurance that the Company will be successful in obtaining stockholder approval or closing the Asset Sale on the anticipated timeline, on the terms currently contemplated, or at all.

Heron Therapeutics' latest quarter

Questions

Did Heron Therapeutics raise or lower its guidance?

Heron Therapeutics (HRTX) gave its guidance on Nov 9, 2026: Free cash flow $45.0M–$60.0M for FY2026; Free cash flow $45.0M–$60.0M for FY2027.

What does Heron Therapeutics expect?

This section provides a general description of our business and operating expenses, as well as other matters that we believe are important to understanding our results of operations and financial condition and in anticipating future trends. This section contains a discussion of the accounting estimates that require a significant level of estimation uncertainty, and changes in which are reasonably likely to have a material effect on our financial condition or results of operations. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowe

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.